Download MendeleyDiscovery of an MLLT1/3 YEATS Domain Chemical Probe.
Moustakim, M., Christott, T., Monteiro, O.P., Bennett, J., Giroud, C., Ward, J., Rogers, C.M., Smith, P., Panagakou, I., Diaz-Saez, L., Felce, S.L., Gamble, V., Gileadi, C., Halidi, N., Heidenreich, D., Chaikuad, A., Knapp, S., Huber, K.V.M., Farnie, G., Heer, J., Manevski, N., Poda, G., Al-Awar, R., Dixon, D.J., Brennan, P.E., Fedorov, O.(2018) Angew Chem Int Ed Engl 57: 16302-16307
- PubMed: 30288907
- DOI: https://doi.org/10.1002/anie.201810617
- Primary Citation of Related Structures:
6HT0, 6HT1 - PubMed Abstract:
YEATS domain (YD) containing proteins are an emerging class of epigenetic targets in drug discovery. Dysregulation of these modified lysine-binding proteins has been linked to the onset and progression of cancers. We herein report the discovery and characterisation of the first small-molecule chemical probe, SGC-iMLLT, for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). SGC-iMLLT is a potent and selective inhibitor of MLLT1/3-histone interactions. Excellent selectivity over other human YD proteins (YEATS2/4) and bromodomains was observed. Furthermore, our probe displays cellular target engagement of MLLT1 and MLLT3. The first small-molecule X-ray co-crystal structures with the MLLT1 YD are also reported. This first-in-class probe molecule can be used to understand MLLT1/3-associated biology and the therapeutic potential of small-molecule YD inhibitors.
Organizational Affiliation:
Structural Genomics Consortium & Target Discovery Institute, University of Oxford, NDMRB, Old Road Campus, Oxford, OX3 7DQ &, OX3 7FZ, UK.
